NCT05627245
Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT05627245
Title Testing the Safety of the Anti-cancer Drugs Tazemetostat and Belinostat in Patients With Lymphomas That Have Resisted Treatment
Recruitment Active, not recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors National Cancer Institute (NCI)
Indications
Therapies
Age Groups: adult | senior
Covered Countries USA

Facility Status City State Zip Country Details
University of California Davis Comprehensive Cancer Center Sacramento California 95817 United States Details
Yale University New Haven Connecticut 06520 United States Details
University of Kansas Clinical Research Center Fairway Kansas 66205 United States Details
University of Kansas Cancer Center Kansas City Kansas 66160 United States Details
University of Kansas Hospital-Westwood Cancer Center Westwood Kansas 66205 United States Details
Rutgers Cancer Institute of New Jersey New Brunswick New Jersey 08903 United States Details
NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center New York New York 10032 United States Details
Ohio State University Comprehensive Cancer Center Columbus Ohio 43210 United States Details
University of Oklahoma Health Sciences Center Oklahoma City Oklahoma 73104 United States Details
Huntsman Cancer Institute/University of Utah Salt Lake City Utah 84112 United States Details
VCU Massey Comprehensive Cancer Center Richmond Virginia 23298 United States Details
*Shaded cells indicate that there was no data available from clinicaltrials.gov for the field